Introducing MEDWatch
- 2 June 1993
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 269 (21), 2765-2768
- https://doi.org/10.1001/jama.1993.03500210065033
Abstract
UNFORTUNATELY, many health professionals do not think to report adverse events that might be associated with medications or devices to the Food and Drug Administration (FDA) or to the manufacturer. That needs to change, and the FDA is taking steps to encourage that to happen.Reports from health professionals of adverse events or product quality problems are essential to ensure the safety of drugs, biologicals, medical devices, and other products regulated by the FDA once they are introduced into the US market.Even the large, well-designed clinical trials that are conducted to gain pre-market approval cannot uncover every problem that can come to light once a product is widely used. A new drug application, for example, typically includes safety data on several hundred to several thousand patients. If an adverse event occurs in perhaps one in 5000 or even one in 1000 users, it could be missed in clinical trialsKeywords
This publication has 5 references indexed in Scilit:
- Antinuclear autoantibodies in women with silicone breast implantsThe Lancet, 1992
- Monitoring Drug Product QualityAmerican Pharmacy, 1992
- Breast implant materials: sense and safetyBritish Journal of Plastic Surgery, 1992
- Adverse Reactions as a Cause of Hospital Admission in the AgedDrugs & Aging, 1992
- The importance of adverse reaction reporting by physicians. Suprofen and the flank pain syndromePublished by American Medical Association (AMA) ,1988